Argentarii’s AstraZeneca AZN Stock Holding History

Argentarii’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,630	Closed	-$240K	–	157
2025 Q1	$240K	Sell	1,630 -112	-6%	-$16.2K	0.12%	140
2024 Q4	$228K	Buy	+1,742	New	+$244K	0.11%	147

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Argentarii's AZN Position: Q2 2025 in Review

Argentarii sold out of AstraZeneca (AZN) in Q2 2025, closing a stake of 1,630 shares — an estimated $240K sold.

Argentarii first reported a position in AZN in Q4 2024 and held it in 2 quarters. The position peaked at $240K in Q1 2025. 1,222 funds tracked by Wall St. Rank hold AZN as of Q2 2025.

Argentarii reported no remaining AstraZeneca position as of Q2 2025 after selling out during the quarter.
Argentarii sold 1,630 AstraZeneca shares in Q2 2025, an estimated $240K.
Argentarii first reported a position in AstraZeneca in Q4 2024 and held it in 2 quarters.
Argentarii's AstraZeneca position peaked at $240K in Q1 2025.
1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.

Based on Argentarii's 13F filing for Q2 2025, filed 14 Jul 2025.